Compare
Nika Pharmaceuticals, Inc vs Skinvisible, Inc. vs Bioadaptives, Inc. vs Regen BioPharma Inc
| Latest fiscal year | Nika Pharmaceuticals, Inc NIKA | Skinvisible, Inc. SKVI | Bioadaptives, Inc. BDPT | Regen BioPharma Inc RGBP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | n/a | $20.0K | $18.3K | $236.6K |
| Revenue growth (YoY) | n/a | 0.0% | +44.3% | 0.0% |
| Gross margin | n/a | 100.0% | 68.4% | n/a |
| Operating margin | n/a | n/m | n/m | -143.1% |
| Net margin | n/a | n/m | n/m | -538.8% |
| Net income | -$76.4K | -$1.06M | -$1.56M | -$1.27M |
| EPS (Diluted) | $0.00 | n/a | -$0.15 | -$0.05 |
| Operating cash flow | -$79.7K | -$38.4K | -$516.0K | -$383.6K |
| Free cash flow | n/a | -$42.5K | -$534.0K | n/a |
| Cash & equivalents | $1.9K | n/a | $215.2K | $69.6K |
| Total assets | $21.0K | $127.6K | $225.9K | $274.6K |
| Total liabilities | $318.6K | $10.39M | $2.36M | $6.56M |
| Shareholders' equity | -$297.6K | -$10.26M | -$2.13M | -$6.28M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 1.05B | 5.40M | 12.01M | 39.37M |
Revenue, most recent five fiscal years
| Fiscal year | Nika Pharmaceuticals, Inc | Skinvisible, Inc. | Bioadaptives, Inc. | Regen BioPharma Inc |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $20.0K Ended 2025-12-31 | $18.3K Ended 2025-12-31 | $236.6K Ended 2025-09-30 |
| 1 year earlier | $0 Ended 2023-12-31 | $20.0K Ended 2024-12-31 | $12.7K Ended 2024-12-31 | $236.6K Ended 2024-09-30 |
| 2 years earlier | $0 Ended 2022-12-31 | $20.0K Ended 2023-12-31 | $28.6K Ended 2023-12-31 | $236.6K Ended 2023-09-30 |
| 3 years earlier | $0 Ended 2021-12-31 | $279.3K Ended 2022-12-31 | $17.2K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $663.4K Ended 2021-12-31 | $19.8K Ended 2021-12-31 | n/a |